 |
NICE recommends mepolizumab for severe and troubling eosinophilic disease Related items from OnMedica The challenges of asthma Childhood asthma overdiagnosed, warn respiratory doctors Asthma costs UK health service at least £1bn every year Vitamin D supplements reduce severe asthma attacks Hospital discharge of children following asthma attack needs improvement |
Friday, 2 December 2016
First-in-class asthma treatment gets provisional green light
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment